Premier Biomedical, Inc. announced that they have filed an application with the U.S. Patent Office on a novel approach to the treatment of Cockayne Syndrome. Cockayne Syndrome (CS) is a rare and devastating neurodegenerative disorder characterized by slow growth, premature aging (progeria), shortened lifespan, moderately to severely inhibited neurological development, hearing loss, eye abnormalities/blindness, and sensitivity to sunlight. Cockayne Syndrome is caused by an inherited gene mutation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0009 USD | -10.00% | -18.18% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 989K | |
+20.59% | 68.31B | |
-1.02% | 48.49B | |
+23.82% | 44.42B | |
+30.26% | 28.29B | |
+7.56% | 19.12B | |
+10.55% | 16.64B | |
-5.73% | 16B | |
-21.45% | 15.84B | |
-20.45% | 13.51B |
- Stock Market
- Equities
- BIEI Stock
- News Premier Biomedical, Inc.
- Premier Biomedical, Inc. Files Patent Application on Cockayne Syndrome Treatment